Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations
Phase of Trial: Phase II/III
Latest Information Update: 30 Dec 2014
At a glance
- Drugs Ponatinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 Dec 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 18 Oct 2013 Status changed from recruiting to suspended according to a media release.